Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $23
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $26
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $26
Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $23
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Argus Research Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Evercore Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $22
Teva Pharmaceutical Indus Analyst Ratings
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $21
Barclays Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $20
Teva Pharmaceutical Indus Analyst Ratings
Argus Upgrades Teva to Buy, Cites Recent Drug Approvals
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings